Upadacitinib (Rinvoq) for Giant Cell Arteritis

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) has been approved by the FDA for treatment of giant cell arteritis. Upadacitinib was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-07-21
DOI: https://doi.org/10.58347/tml.2025.1733b
Citations: 1
Primary Topic: Vasculitis and related conditions
Type: article
Field-Weighted Citation Impact: 1.52

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Upadacitinib (Rinvoq) for Giant Cell Arteritis

Jul 21, 2025

1 citations

The medical letter on drugs and therapeutics/The medical letter

Vasculitis and related conditions

1.52

article

Upadacitinib (Rinvoq) for Giant Cell Arteritis

July 21, 2025article en

1 citations

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1733)

Openalex Percentile: Top 16%

Vasculitis and related conditions

1.52

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Upadacitinib (Rinvoq) for Giant Cell Arteritis · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS